Drug recall · April 1, 2020
Nystatin Oral Suspension recall
Why: SubPotent Drug: Low out-of-specification results for assay testing.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Nystatin Oral Suspension, USP, 100,000 units per mL, Cherry/Peppermint Flavor, 16 fl oz (473 mL) bottle, Rx ONLY, pai Pharmaceutical Associates, Inc., Greenville, SC 29605; NDC 0121-0810-16.
- Lots / codes
Lot: BE85, Exp. 11/2020
- Quantity
- 7416 bottles
- Company
- PAI Holdings, LLC. dba Pharmaceutical Associates Inc, Greenville, SC
- Distribution
- Nationwide in the USA.
- Initiated
- March 19, 2020 · Voluntary: Firm initiated
- Classified
- March 25, 2020
- Reported
- April 1, 2020
- Ended
- September 22, 2021
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Nystatin
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.